These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11038435)

  • 21. Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.
    Arvidsson M; Dahl ML; Beck O; Ackehed G; Nordin K; Rosenborg S
    Eur J Clin Pharmacol; 2020 Feb; 76(2):229-237. PubMed ID: 31786618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid.
    Chan YP; Swanson JM; Soldin SS; Thiessen JJ; Macleod SM; Logan W
    Pediatrics; 1983 Jul; 72(1):56-9. PubMed ID: 6866592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast.
    Schug BS; Brendel E; Wonnemann M; Wolf D; Wargenau M; Dingler A; Blume HH
    Eur J Clin Pharmacol; 2002 May; 58(2):119-25. PubMed ID: 12012144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
    Childress A; Stark JG; McMahen R; Engelking D; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog.
    Giorgi M; Prise U; Soldani G; Neri D; Lavy E
    Vet Res Commun; 2010 Jun; 34 Suppl 1():S73-7. PubMed ID: 20454855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
    Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of food on the pharmacokinetics of methylphenidate.
    Midha KK; McKay G; Rawson MJ; Korchinski ED; Hubbard JW
    Pharm Res; 2001 Aug; 18(8):1185-9. PubMed ID: 11587491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.
    Spencer TJ; Biederman J; Martin JM; Moorehead TM; Mirto T; Clarke A; Batchelder H; Faraone SV
    Postgrad Med; 2012 Jan; 124(1):166-73. PubMed ID: 22314126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.